Working… Menu

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03333616
Recruitment Status : Recruiting
First Posted : November 7, 2017
Last Update Posted : July 7, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Bradley A. McGregor, Dana-Farber Cancer Institute